Black race and CA 19-9 nonproduction is associated with limited pathologic response to neoadjuvant chemotherapy in patients with localized pancreatic cancer

被引：0
|
作者：
Martos, Mary P.
Dickey, Erin M.
Abdilleh, Kawther
Ahmad, Syed A.
Maithel, Shishir K.
Hammill, Chet W.
Kim, Hong Jin
Abbott, Daniel E.
Kooby, David A.
Parikh, Alexander A.
Hosein, Peter J.
Merchant, Nipun B.
Datta, Jashodeep
Hester, Caitlin A.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 17期
关键词：
D O I：
10.1158/1538-7445.PANCREATIC24-A019
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A019
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Interfering Effect of Black Tea Consumption on Diagnosis of Pancreatic Cancer by CA 19-9
    Al-Janabi A.A.H.S.
    Tawfeeq E.F.
    Journal of Gastrointestinal Cancer, 2017, 48 (2) : 148 - 150
  • [32] Sustained Carbohydrate Antigen 19-9 Response to Neoadjuvant Chemotherapy in Borderline Resectable Pancreatic Cancer Predicts Progression and Survival
    Rose, J. Bart
    Edwards, Alicia M.
    Rocha, Flavio G.
    Clark, Carolyn
    Alseidi, Adnan A.
    Biehl, Thomas R.
    Lin, Bruce S.
    Picozzi, Vincent J.
    Helton, W. Scott
    ONCOLOGIST, 2020, 25 (10): : 859 - 866
  • [33] MAGNITUDE OF CA19-9 DECLINE IN RESPONSE TO NEOADJUVANT CHEMORADIATION IS ASSOCIATED WITH OVERALL SURVIVAL IN PATIENTS WITH PANCREATIC CANCER
    Thalji, Sam
    Hall, William
    Aldakkak, Mohammed
    Christians, Kathleen
    Clarke, Callisia N.
    George, Ben
    Kamgar, Mandana
    Hunt, Bryan
    Madhavan, Srivats
    Kulkarni, Naveen
    Erickson, Beth A.
    Evans, Douglas B.
    Tsai, Susan
    GASTROENTEROLOGY, 2021, 160 (06) : S902 - S902
  • [34] Decrease of CA 19-9 in patients with advanced pancreatic cancer (APC) undergoing chemotherapy predicts survival time
    Pohlank, K.
    Hilbig, A.
    Pelzer, U.
    Stieler, J.
    Roll, L.
    Goerke, A.
    Sinn, M.
    Doerken, B.
    Riess, H.
    Oettle, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [35] Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer
    Halm U.
    Schumann T.
    Schiefke I.
    Witzigmann H.
    Mössner J.
    Keim V.
    British Journal of Cancer, 2000, 82 (5) : 1013 - 1016
  • [36] Tumor growth kinetics by CA 19-9 in patients with unresectable pancreatic cancer receiving chemotherapy: A retrospective analysis
    Colloca, Giuseppe A.
    Venturino, Antonella
    Guarneri, Domenico
    PANCREATOLOGY, 2020, 20 (06) : 1189 - 1194
  • [37] Serum levels of CA 19-9 in patients with pancreatic cancer and liver cirrhosis
    Kadayifci, A
    Simsek, H
    Usalan, C
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 1995, 14 (04) : 435 - 437
  • [38] Prognostic value of CA 19-9 in patients with pancreatic cancer treated with Gemcitabine
    Halm, U
    Schuhmann, T
    Keim, V
    Moessner, J
    GASTROENTEROLOGY, 1999, 116 (04) : A1129 - A1129
  • [39] CA 19-9 predicts resectability of pancreatic cancer even in jaundiced patients
    Santucci, Nicolas
    Facy, Olivier
    Ortega-Deballon, Pablo
    Lequeu, Jean-Baptiste
    Rat, Paul
    Rat, Patrick
    PANCREATOLOGY, 2018, 18 (06) : 666 - 670
  • [40] Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer
    Halm, U
    Schumann, T
    Schiefke, I
    Witzigmann, H
    Mössner, J
    Keim, V
    BRITISH JOURNAL OF CANCER, 2000, 82 (05) : 1013 - 1016
12345